Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Human Brain Nucleus Incertus: A New Target in Dementia?
Intorcia, Anthony J., Suazo, Crystal , Nolz, Jennifer, Tallant, Lauren , Plamondon, Julie, Beach, Thomas G. , Ávila, Camila de , Serrano, Geidy E. , Caron, Alexandre , Gundlach, Andrew L. , Mastroeni, Diego

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.071647 Get It

AbstractBackgroundThe brainstem nucleus incertus (NI) or ‘uncertain nucleus’, was originally described by Streeter in 1903 as a midline region in the floor of the fourth ventricle of the human brain with an ‘unknown’ function. A century later, the NI has been shown to play a key role in memory formation in rodents, through direct and indirect inhibition of the hippocampus; and the anatomy of the NI and its projections throughout the brain have been systematically mapped in rats, mice, and primates, but not in humans. In these novel studies, we mapped the human NI using the neuropeptide, relaxin‐3 (RLN3), as neurochemical marker. In rodents, RLN3 is produced mostly in NI neurons with some subsidiary positive cells in the periaqueductal gray and an area dorsal to the substantia nigra.MethodsSerial, free‐floating coronal sections of formalin‐fixed postmortem tissue were prepared from the pons of an adult female (aged 96 years) without a history of dementia or other neurological disorders, provided by the Banner Brain and Body Donation Program, Sun City, Arizona, USA. Using immunohistochemistry, we first identified the NI by mapping the distribution of microtubule‐associated protein‐2 (MAP2) and RLN3. The specificity of the RLN3 antibody used was verified in a dot‐blot using native RLN3 peptide. We also investigated the presence of markers detected in the NI of rats ‐ glutamic acid dehydrogenase‐65/67 (GAD65/67) and corticotropin‐releasing factor type 1 receptor (CRF1); and used a phosphorylated‐tau (AT8) to determine if the NI displayed tau accumulation.ResultsDetection of MAP2‐immunoreactivity revealed the neuronal distribution throughout the pons. RLN3‐immunoreactivity was detected in neurons in the dorsal, anterior‐medial region, revealing the broad anatomy of the human NI. Neurons within this same area were also positive for GAD65/67‐ and CRF1‐immunoreactivity, in line with previous studies; and AT8‐immunoreactivity was also detected.ConclusionsRLN3 is present in neurons of the human NI and aspects of its anatomy are shared across species, including the macaque. Accumulation of phosphorylated‐tau in the NI suggests its possible involvement in the pathology of Alzheimer’s disease and related dementias. Further comparative studies are required to better understand the neurochemical anatomy of the human NI.
Curriculum‐based CME Programming Results in Comprehensive Improvements in Knowledge, Competence, and Confidence in Diagnosing Early Forms of Alzheimer’s Disease Among a Global Audience of PCPs and Neurologists
Finnegan, Thomas , Stan, Adriana, McFarland, Frances, Chatterjee‐Shin, Piyali, Guedj, Philippe, Cohen, Sharon , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S11 | Pages: No page available

10.1002/alz.082156 Get It

Abstract Background Early diagnosis of Alzheimer’s disease (AD) is crucial for ensuring patients have timely access to essential care. Given the symptoms of early AD are often subtle, it is important that both primary care physicians (PCPs) and neurologists are able to diagnose their patients. Several sources of evidence have indicated that most PCPs and neurologists lack knowledge, competence, and confidence regarding recognition of early forms of AD. To address the clinical practice gaps, a series of CME‐certified programs covering the symptoms, assessment, and diagnosis of early forms of AD were developed. Method The data presented here are based on outcomes from four online CME‐certified multimedia programs housed on a single destination page. Each CME‐certified program utilized expert physicians to educate learners on recognizing early forms of AD. Each CME program asked a series of pre‐post questions designed to assess immediate changes in knowledge, competence, or confidence. The questions were grouped into clinically relevant themes. The educational effect for all of the programs was determined by using a paired‐samples t‐test to identify significant differences between pre‐ and post‐assessment responses for each question. Data across all four programs were collected from February 2022 through December 2022. All four programs were promoted to an audience of US‐ and ex‐US physicians. Result Participation across the four programs ranged from 543 to 2,510 PCPs and 256 to 1,025 neurologists. PCPs and neurologists demonstrated significant (P<0.05) pre‐vs post education improvements on the following themes: biomarkers in AD, clinical trial outcomes, cognitive assessment scales, diagnosis of AD, diagnosis of mild cognitive impairment (MCI), and symptoms differentiating AD from MCI. Participation in the education also significantly (P<0.001) improved confidence in the identification of early forms of AD among PCPs and neurologists. No substantial differences in knowledge, competence, or confidence were seen for either clinician group based on geographic location of the learner. Conclusion The results indicated that clinicians who participated in CME‐certified curriculum‐based education in multiple formats were better prepared to recognize early forms of AD. Future education should continue to discuss the use of clinical strategies to recognize early forms of AD.
Social engagement, amyloid burden, and dementia: the Atherosclerosis Risk in Communities (ARIC)‐PET study
Groechel, Renée C. , Liu, Albert C. , Palta, Priya, Sharrett, Richey, Wong, Dean F. , Liu, Chelsea , Knopman, David S. , Koton, Silvia , Kucharska‐Newton, Anna , Lutsey, Pamela L. , Mosley, Thomas H. , Walker, Keenan A. , Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.081623 Get It

AbstractBackgroundAlthough amyloid deposition in the brain is often associated with subsequent dementia risk, not everyone with brain amyloid will develop dementia. This discrepancy illustrates the potential importance that risk factors and lived experiences may have in modifying this association. Compared to participants with low social engagement (SE) in mid‐life, we hypothesized that participants with high mid‐life SE will show a weaker association between amyloid burden and incident dementia.MethodWe included data from 310 non‐demented participants of the Atherosclerosis Risk in Communities (ARIC)‐PET study. Social support and isolation were assessed via interviewer‐administered questionnaires (Visit 2; 1990 – 1992). Based upon categorization of both factors, participants were classified as having high, intermediate, or low mid‐life SE (Table 1). Brain amyloid was evaluated with florbetapir PET (Visit 5; 2011‐2014). Elevated amyloid burden was defined as standardized uptake value ratio (SUVR) >1.2 in the global cortex. Incident dementia cases were identified from visit 5 through 2019 through ongoing surveillance utilizing in‐person neurocognitive testing, informant interviews, and hospitalization codes. Relative contributions of mid‐life SE and elevated florbetapir SUVR to incident dementia, independently and with multiplicative interaction terms, were evaluated with Cox regression models, adjusted for demographics, APOEe4 and vascular risk factorsResultAmong 310 participants, 48 developed dementia (median follow‐up: 4.7 years). Mid‐life SE and elevated SUVR each independently predicted dementia risk but did not interact on a multiplicative scale. Participants with high or intermediate mid‐life SE, relative to low mid‐life SE, were less likely to develop dementia (Table 2). Although the interaction between mid‐life SE and elevated SUVR was not significant, stratified models suggested a stronger association between amyloid burden and dementia in participants with high mid‐life SE (Table 3).ConclusionGreater mid‐life SE was associated with lower odds of developing dementia, independent of elevated SUVR. Although protective, there was no strong evidence for effect modification of mid‐life SE on the association between amyloid and dementia risk. Future longitudinal studies evaluating the potential influence of social factors measured throughout the life course are needed to inform our understanding as to what factors may preserve cognition in the presence of elevated brain pathology.
Severe aortic stenosis: secular trends of incidence and outcomes
Benfari, Giovanni , Essayagh, Benjamin , Ye, Zi , Medina‐Inojosa, José R. , Messika–Zeitoun, David , Prendergast, Bernard , Wong, Benjamin F., Thapa, Prabin , Inojosa, Jose Medina, Messika-Zeitoun, David , Prendergast, Bernard D , Thapa, Prabin , Enriquez-Sarano, Maurice , Medina-Inojosa, José R , Benfari, Giovanni , Essayagh, Benjamin , Michelena, Héctor I. , Ribichini, Flavio Luciano , Crestanello, Juan A. , Enriquez‐Sarano, Maurice

Mayo Clinic

European Heart Journal | December 22, 2023 | Volume: 45 | Issue: 21 | Pages: 1877-1886

10.1093/eurheartj/ehad887 | PMID 38190428 Get It

Abstract Background and Aims Severe aortic stenosis (AS) is the guideline-based indication for aortic valve replacement (AVR), which has markedly increased with transcatheter approaches, suggesting possible increasing AS incidence. However, reported secular trends of AS incidence remain contradictory and lack quantitative Doppler echocardiographic ascertainment. Methods All adults residents in Olmsted County (MN, USA) diagnosed over 20 years (1997–2016) with incident severe AS (first diagnosis) based on quantitatively defined measures (aortic valve area ≤ 1 cm2, aortic valve area index ≤ 0.6 cm2/m2, mean gradient ≥ 40 mmHg, peak velocity ≥ 4 m/s, Doppler velocity index ≤ 0.25) were counted to define trends in incidence, presentation, treatment, and outcome. Results Incident severe AS was diagnosed in 1069 community residents. The incidence rate was 52.5 [49.4–55.8] per 100 000 patient-year, slightly higher in males vs. females and was almost unchanged after age and sex adjustment for the US population 53.8 [50.6–57.0] per 100 000 residents/year. Over 20 years, severe AS incidence remained stable (P = .2) but absolute burden of incident cases markedly increased (P = .0004) due to population growth. Incidence trend differed by sex, stable in men (incidence rate ratio 0.99, P = .7) but declining in women (incidence rate ratio 0.93, P = .02). Over the study, AS clinical characteristics remained remarkably stable and AVR performance grew and was more prompt (from 1.3 [0.1–3.3] years in 1997–2000 to 0.5 [0.2–2.1] years in 2013–16, P = .001) but undertreatment remained prominent (&gt;40%). Early AVR was associated with survival benefit (adjusted hazard ratio 0.55 [0.42–0.71], P &lt; .0001). Despite these improvements, overall mortality (3-month 8% and 3-year 36%), was swift, considerable and unabated (all P ≥ .4) throughout the study. Conclusions Over 20 years, the population incidence of severe AS remained stable with increased absolute case burden related to population growth. Despite stable severe AS presentation, AVR performance grew notably, but while declining, undertreatment remained substantial and disease lethality did not yet decline. These population-based findings have important implications for improving AS management pathways.
Sex differences in brain atrophy in dementia with Lewy bodies
Oltra, Javier , Habich, Annegret , Nedelská, Zuzana , Przybelski, Scott A. , Diaz‐Galvan, Patricia , Lowe, Val J. , Oppedal, Ketil , Philippi, Nathalie , Blanc, Frédéric , Barkhof, Frederik , Padovani, Alessandro , Massa, Federico , Kramberger, Milica G. , Snædal, Jón , Walker, Zuzana , Antonini, Angelo , Segura, Bàrbara , Westman, Eric , Kantarci, Kejal , Antonini, Angelo , Walker, Zuzana , Nedelska, Zuzana , Westman, Eric , Kantarci, Kejal , Barkhof, Frederik , Habich, Annegret , Diaz-Galvan, Patricia , Padovani, Alessandro , Massa, Federico , Segura, Barbara , Schwarz, Christopher G. , Inguanzo, Anna , González, Maria Camila , Lemstra, Afina W. , Hort, Jakub , Rektorová, Irena , Bonanni, Laura , Taylor, John‐Paul , Dierks, Thomas , Junqué, Carme , Boeve, Bradley F. , Aarsland, Dag , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | December 22, 2023 | Volume: 20 | Issue: 3 | Pages: 1815-1826

10.1002/alz.13571 | PMID 38131463 Get It

Abstract INTRODUCTION Sex influences neurodegeneration, but it has been poorly investigated in dementia with Lewy bodies (DLB). We investigated sex differences in brain atrophy in DLB using magnetic resonance imaging (MRI). METHODS We included 436 patients from the European‐DLB consortium and the Mayo Clinic. Sex differences and sex‐by‐age interactions were assessed through visual atrophy rating scales ( n = 327; 73 ± 8 years, 62% males) and automated estimations of regional gray matter volume and cortical thickness ( n = 165; 69 ± 9 years, 72% males). RESULTS We found a higher likelihood of frontal atrophy and smaller volumes in six cortical regions in males and thinner olfactory cortices in females. There were significant sex‐by‐age interactions in volume (six regions) and cortical thickness (seven regions) across the entire cortex. DISCUSSION We demonstrate that males have more widespread cortical atrophy at younger ages, but differences tend to disappear with increasing age, with males and females converging around the age of 75. Highlights Male DLB patients had higher odds for frontal atrophy on radiological visual rating scales. Male DLB patients displayed a widespread pattern of cortical gray matter alterations on automated methods. Sex differences in gray matter measures in DLB tended to disappear with increasing age.
SEVERE ALZHEIMER’S DEMENTIA ALTERS THE RELATIONSHIP BETWEEN EXECUTIVE FUNCTION AND FALLS
Delgado, Ferdinand , Beach, Thomas G. , Ananian, Cheryl Der, Yu, Fang , MacKinnon, David P. , Peterson, Daniel S. , Ofori, Edward , Adler, Charles H.

Mayo Clinic

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 1117-1118

10.1093/geroni/igad104.3588 Get It

Abstract Falls are a public health concern for older adults, particularly those with cognitive impairments, like mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia. Executive function (EF) is linked to falls in older adults, but little is known about the relationship between individual EF assessments and falls in individuals with varying cognitive statuses. Using cross-sectional secondary data analyses with binary logistic regression, we examined the associations between EF assessments (Trail Making Test (ΔTMT), Digit Span (DS), Stroop test, Clock Drawing Test, and phonemic/semantic fluency tests) and falls (fall history and subsequent falls) in 466 participants (aged 66-103) with either intact cognition, MCI, or AD dementia. Surprisingly, a significant interaction effect emerged with AD dementia and EF assessments (ΔTMT, DS, and semantic fluency), revealing that individuals with AD dementia with worse EF had a lower probability of prior fall history. These findings were influenced by a low percentage of reported falls in people with severe AD dementia. Further stratified analysis of the interaction effects showed that DS and semantic fluency were significantly associated with fall history in people without AD dementia. While some EF assessments were individually associated with falls, interpretations should be made cautiously, especially considering the appropriateness of the assessments for specific populations. The counterintuitive result may stem from factors specific to severe AD dementia. In conclusion, this study uncovers complex interactions between cognitive status, EF assessments, and fall history, and the potential for further investigation to enhance our understanding of falls in individuals with severe AD dementia.
CIRCULATING SASP FACTORS ARE ELEVATED IN PATIENTS WITH POSTOPERATIVE DELIRIUM
White, Thomas A. , Atkinson, Elizabeth J. , Palmer, Allyson K. , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 21, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 101-101

10.1093/geroni/igad104.0327 Get It

Abstract Aging, a major risk factor for delirium, is associated with accumulation of senescent cells in many tissues of the body. Senescent cells produce a host of proinflammatory and tissue remodeling factors collectively termed the senescence-associated secretory phenotype (SASP), which are secreted into circulation. The relationship between increased senescent cell burden and risk of delirium is not known. This study aimed to determine whether changes in circulating SASP proteins are associated with increased risk of postoperative delirium in cognitively intact older adults. Participants were recruited among patients scheduled for surgical or transcatheter aortic valve replacement, and blood was obtained at the presurgical visit. SASP factors were measured using commercially available multiplex magnetic bead immunoassays based on Luminex xMAP multianalyte profiling platform and analyzed on a MAGPIX system. Activin A concentration was determined by a Quantikine ELISA kit. Delirium cases were identified by manual chart abstraction, utilizing the problem list, ICD-10 codes, clinical notes, and nursing flowsheets. Eight of 62 (12.9%) of patients within the cohort developed postoperative delirium. Length of stay was significantly longer for patients who developed delirium (10.6 days) versus patients without delirium (6 days). Concentrations of SASP factors Activin A and PAPP-A were significantly higher in plasma of patients with delirium vs. those who did not develop delirium. IL-1 alpha concentration was significantly lower in patients with delirium vs without delirium. Other SASP factors measured were not statistically different between groups. More study is needed to determine whether these changes are directly related to increased senescent cell burden.
Cardiorespiratory fitness and morbidity and mortality in patients with non-small cell lung cancer: a prospective study with propensity score weighting
Dun, Yaoshan , Cui, Ni, Wu, Shaoping , Fu, Siqian, Ripley-Gonzalez, Jeffrey W. , Zhou, Nanjiang , Zeng, Tanghao, Li, Dezhao, Lau, Wan Yee , Du, Yang , Squires, Ray W. , Olson, Thomas P. , Liu, Suixin , Dun, Yaoshan , Chen, Mi , Ren, Yu , Thomas, Randal J. , Liu, Suixin

Mayo Clinic

Annals of Medicine | December 21, 2023 | Volume: 55 | Issue: 2 | Pages: No page available

10.1080/07853890.2023.2295981 | PMID 38128485 Get It

The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Mathie, Alistair , Peters, John A. , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Davies, Jamie A. , Beuve, Annie , Brouckaert, Peter, Burnett, John C. , Friebe, Andreas , Garthwaite, John , Koesling, Doris , Kühn, Michaela , Potter, Lincoln R. , Stasch, Johannes‐Peter, Alexander, Stephen P H , Mathie, Alistair A , Peters, John A , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , MacEwan, David , Monie, Tom P , Kelly, Eamonn , Hobbs, Adrian J , Russwurm, Michael , Schmidt, Harald , Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 21, 2023 | Volume: 180 | Issue: S2 | Pages: No page available

10.1111/bph.16180 | PMID 38123155 Get It

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and nearly 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16180. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.